• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Cencora Announces Date and Time for First Quarter Fiscal 2025 Earnings Release

    1/8/25 7:30:00 AM ET
    $COR
    Other Pharmaceuticals
    Health Care
    Get the next $COR alert in real time by email

    Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the First Quarter of Fiscal 2025 on Wednesday, February 5, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on February 5, 2025.

    Participating in the conference call will be:

    Robert P. Mauch, President & Chief Executive Officer

    James F. Cleary, Executive Vice President & Chief Financial Officer

    The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.

    To access the call via telephone from within the United States and Canada, dial (833) 470-1428. From outside the United States and Canada, dial +1 (404) 975-4839. The access code for the call will be 427679.

    Replays of the call will be made available via telephone and webcast. A replay of the webcast will be posted on investor.cencora.com approximately one hour after the completion of the call and will remain available for one year. The telephone replay will also be available approximately one hour after the completion of the call and will remain available for 7 days. To access the telephone replay from within the United States and Canada, dial (866) 813-9403. From outside the United States, dial +1 (929) 458-6194. The access code for the replay is 402593.

    Please check the website investor.cencora.com for updates regarding the timing of the live webcasts and for replay information.

    About Cencora

    Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. Cencora partners with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on Cencora for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Cencora's 46,000+ worldwide team members contribute to positive health outcomes through the power of Cencora's purpose: Cencora is united in its responsibility to create healthier futures. Cencora is ranked #10 on the Fortune 500 and #18 on the Global Fortune 500 with more than $290 billion in annual revenue. Learn more at investor.cencora.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250107768923/en/

    Bennett S. Murphy

    Senior Vice President, Head of Investor Relations and Treasury

    [email protected]

    Get the next $COR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $COR

    DatePrice TargetRatingAnalyst
    6/3/2025$337.00Equal Weight → Overweight
    Wells Fargo
    12/4/2024$280.00Outperform
    Mizuho
    9/18/2024$275.00 → $245.00Buy → Neutral
    BofA Securities
    2/26/2024$261.00Outperform
    Leerink Partners
    1/3/2024$242.00Overweight
    Barclays
    12/14/2023$213.00Equal Weight
    Wells Fargo
    12/14/2021$162.00 → $170.00Buy → Neutral
    Citigroup
    11/26/2021$136.00 → $170.00Sector Perform
    RBC Capital
    More analyst ratings

    $COR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cencora upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded Cencora from Equal Weight to Overweight and set a new price target of $337.00

      6/3/25 7:24:57 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Mizuho resumed coverage on Cencora with a new price target

      Mizuho resumed coverage of Cencora with a rating of Outperform and set a new price target of $280.00

      12/4/24 7:30:44 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora downgraded by BofA Securities with a new price target

      BofA Securities downgraded Cencora from Buy to Neutral and set a new price target of $245.00 from $275.00 previously

      9/18/24 8:27:47 AM ET
      $COR
      Other Pharmaceuticals
      Health Care

    $COR
    SEC Filings

    See more
    • SEC Form 11-K filed by Cencora Inc.

      11-K - Cencora, Inc. (0001140859) (Filer)

      6/17/25 4:33:24 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - Cencora, Inc. (0001140859) (Filer)

      6/6/25 4:01:51 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • SEC Form SD filed by Cencora Inc.

      SD - Cencora, Inc. (0001140859) (Filer)

      5/30/25 4:11:02 PM ET
      $COR
      Other Pharmaceuticals
      Health Care

    $COR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cencora Elects Lori J. Ryerkerk to Its Board of Directors

      Cencora, Inc. (NYSE:COR) today announced that its Board of Directors has elected Lori J. Ryerkerk as a new independent director, effective June 1, 2025. "Ms. Ryerkerk's experience in complex, global supply chains will further strengthen the Board's expertise as we continue supporting the company's long-term growth. Her appointment reflects the Cencora Board's ongoing commitment to leaders who can help us contribute to driving stakeholder value," said Mark Durcan, Lead Independent Director. "Lori's experience as a public company CEO, leading a global specialties chemical company with extensive operations and logistics, will bring valuable insight as we execute against our strategy and bu

      5/28/25 7:30:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Reports Fiscal 2025 Second Quarter Results

      Revenue of $75.5 billion for the Second Quarter, a 10.3 percent Increase Year-Over-Year Second Quarter GAAP Diluted EPS of $3.68 and Adjusted Diluted EPS of $4.42 Adjusted Diluted EPS Guidance Range Raised to $15.70 to $15.95 for Fiscal 2025 Cencora, Inc. (NYSE:COR) reported that in its fiscal year 2025 second quarter ended March 31, 2025, revenue increased 10.3 percent year-over-year to $75.5 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $3.68 for the second quarter of fiscal 2025 compared to $2.09 in the prior year second quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described

      5/7/25 6:30:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Announces Date and Time for Second Quarter Fiscal 2025 Earnings Release

      Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2025 on Wednesday, May 7, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 7, 2025. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access the call via

      3/28/25 7:00:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care